Current Status and Prospects of Regional Collaborative Pathways for Management of Acute Coronary Syndrome in Japan ― A Nationwide Survey ―
Regional collaborative clinical pathways for ACS patients in Japan show variable implementation across prefectures, with approximately one-third of prefectures having established pathways. Future efforts should prioritize the establishment of comprehensive, sustainable, and standardized pathways to optimize ACS management and improve patient outcomes nationwide.
Authors
- Masashi Koga
- Yuji Ikari (ORCID: https://orcid.org/0000-0001-5686-4324)
- Masaomi Gohbara (ORCID: https://orcid.org/0000-0002-3243-4028)
- Mutsuo Harada (ORCID: https://orcid.org/0000-0001-8338-6284)
- Kiyoshi Hibi (ORCID: https://orcid.org/0000-0002-1543-1183)
- Kenji Onoue (ORCID: https://orcid.org/0000-0003-3233-4913)
- Hiroshi Suzuki (ORCID: https://orcid.org/0000-0002-8698-7357)
- Issei Komuro (ORCID: https://orcid.org/0000-0002-0714-7182)
- Yoshihiro J. Akashi (ORCID: https://orcid.org/0000-0001-7670-7326)
- Junya Ako (ORCID: https://orcid.org/0000-0001-6645-6404)
- Yoshihiko Saito (ORCID: https://orcid.org/0000-0001-5574-3571)
- Norihiko Kamioka (ORCID: https://orcid.org/0000-0001-7222-6197)
- Yoshiyasu Minami (ORCID: https://orcid.org/0000-0003-2745-9682)
- Kazuma Tashiro
- Kazuki Fukui
Institutions
- Tokai University (JP)
- National Archives and Records Administration (US)
- St. Marianna University School of Medicine (JP)
- Yokohama City University Medical Center (JP)
- Kanagawa Cardiovascular and Respiratory Center (JP)
- SHOWA Medical University Fujigaoka Hospital (JP)
- Kitasato University (JP)
- Nara Medical University (JP)
- The University of Tokyo (JP)
- International University of Health and Welfare (JP)
- Yokohama City University (JP)
Publication Details
- Journal
- Circulation Journal
- Published
- 2025-01-27
- DOI
- https://doi.org/10.1253/circj.cj-24-0714
- Citations
- 5
- Primary Topic
- Antiplatelet Therapy and Cardiovascular Diseases
- Type
- article
- Field-Weighted Citation Impact
- 6.94
Funders
- Amgen